Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsVentura County Praluent Coverage Policy | OpenPaye…
    Ask Trek AI about this page
    RetiredVentura County Health Care PlanPolicy N/A

    Praluent (alirocumab) Coverage Criteria

    Customize your policy alerts

    Sign up for all venturacountyhealthcareplan policy alerts

    Know when venturacountyhealthcareplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and benefit coverage for Praluent (alirocumab), a PCSK9 inhibitor used for hyperlipidemia. The policy designates Praluent and Repatha as not covered benefits and directs rejection at the retail pharmacy or ESI level.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyPraluent (alirocumab) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeArchived policy
    Effective DateOct 27, 2015
    Last ReviewJan 22, 2019
    Next Review DateN/A
    Key ActionClaims for Praluent and Repatha should reject at the retail pharmacy or ESI level.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Not coveredCoverage status for Praluent and Repatha
    2PCSK9 inhibitor products identified as not covered
    75 or 150 mgAlirocumab dose strengths per administration
    4–8 weeksPeriod for evaluating response before potential dose increase

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Determination

    Not covered benefit

    The medication is not covered at this time.

    Not covered: Praluent (alirocumab) and Repatha are designated as not covered benefits because cardiovascular outcome data were not available at the time of review.

    Claims should reject at the retail pharmacy or ESI level.

    Praluent (alirocumab) and Repatha are not covered benefits under this policy. Claims for these products should reject at the retail pharmacy or ESI level.

    Coverage and Claims Handling

    Denial Risk

    Not a Covered Benefit

    Praluent and Repatha are not covered benefits at this time. Claims should reject at the retail pharmacy or ESI level.

    • Affected products: Praluent and Repatha.
    • Coverage status: Not a covered benefit.
    • Claims handling: Reject at the retail pharmacy or ESI level.

    Clinical Background

    Alirocumab is a human monoclonal antibody that inhibits PCSK9 binding to hepatic LDL receptors. By preserving these receptors, it increases clearance of circulating LDL cholesterol and lowers LDL-C. At the time of policy review, cardiovascular outcome data were not available.

    Key Terms

    Alirocumab
    DefinitionA human monoclonal antibody (IgG1 isotype) that binds to proprotein convertase subtilisin kexin type 9 (PCSK9).
    PCSK9 inhibitor
    DefinitionA therapeutic lipid-lowering category consisting of agents that inhibit PCSK9.
    Policy Summary
    PayerVentura County Health Care Plan
    PolicyPraluent (alirocumab) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeArchived policy
    Effective DateOct 27, 2015
    Last ReviewJan 22, 2019
    Next Review DateN/A
    Key ActionClaims for Praluent and Repatha should reject at the retail pharmacy or ESI level.
    SourceLink
    On This Page
    Coverage DeterminationCoverage and Claims HandlingClinical BackgroundKey Terms